Xaracoll is a drug owned by Innocoll Pharmaceuticals. It is protected by 2 US drug patents filed from 2020 to 2023 out of which none have expired yet. Based on its patents and exclusivities, its generic launch date is estimated to be Jan 09, 2033. Details of Xaracoll's patents and their expiration are given in the table below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| These drug patents focus on the other aspects of the drug like dosage, mode of administration (oral, tablet, capsules, liquids etc). | |||
| US11746141 | Modified collagen |
Jan, 2033
(7 years from now) | Active |
| USRE47826 | Drug delivery device for providing local analgesia, local anesthesia or nerve blockage |
May, 2029
(4 years from now) | Active |
A patent's expiry date may change depending upon legal activities going on that patent. Critical activities like abandoning of a patent, term extension of a patent or amendment of its claims can increase or decrease the life of a patent hence affecting its expiry date and in turn affecting the generic launch date of that drug. Tracking these ongoing activities on a patent application helps to keep an eye on the latest developments in the patent process of the drug which can give an idea of how early a drug's generic could be available. The next section provides a list of recent legal activities on Xaracoll's patents.
Latest Legal Activities on Xaracoll's Patents
Given below is the list of recent legal activities going on the following patents of Xaracoll.
| Activity | Date | Patent Number |
|---|---|---|
 | ||
| Patent Issue Date Used in PTA Calculation Critical | 05 Sep, 2023 | US11746141 |
| Recordation of Patent eGrant | 05 Sep, 2023 | US11746141 |
| Recordation of Patent Grant Mailed Critical | 05 Sep, 2023 | US11746141 |
| Patent eGrant Notification | 05 Sep, 2023 | US11746141 |
| Mail Patent eGrant Notification | 05 Sep, 2023 | US11746141 |
| Email Notification Critical | 05 Sep, 2023 | US11746141 |
| Email Notification Critical | 18 Aug, 2023 | US11746141 |
| Issue Notification Mailed Critical | 16 Aug, 2023 | US11746141 |
| Dispatch to FDC | 20 Jul, 2023 | US11746141 |
| Application Is Considered Ready for Issue Critical | 20 Jul, 2023 | US11746141 |
FDA has granted several exclusivities to Xaracoll. Till the time these exclusivities are active, no other company can market a generic or bioequivalent version of Xaracoll, regardless of the status of it's patents. These exclusivities hence play a crucial role in delaying the generic launch. Given below are details of the exclusivities granted to Xaracoll.
Exclusivity Information
Xaracoll holds 1 exclusivities. All of its exclusivities have expired in 2023. Details of Xaracoll's exclusivity codes and their expiration dates are given below.
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Product(NP) | Aug 28, 2023 |
US patents provide insights into the exclusivity only within the United States, but Xaracoll is protected by patents in multiple countries. Understanding the full scope of patent protection is crucial in strategizing market entry. By looking at the broader patent landscape, you can identify markets with weaker patent protection which could be ideal generic entry points. The following section offers details on Xaracoll's family patents as well as insights into ongoing legal events on those patents.
Xaracoll's Family Patents
Explore Our Curated Drug Screens
Generic Launch
Generic Release Date:
Xaracoll's generic launch date based on the last expiry date of its patents and exclusivities combined is estimated to be Jan 09, 2033 (This date is subject to change depending upon the patent filing activities by the drug owner or exclusivity additions to its drug application)
Xaracoll Generic API suppliers:
Bupivacaine Hydrochloride is the generic name for the brand Xaracoll. 13 different companies have already filed for the generic of Xaracoll, with Hospira having the maximum number of approved applications. Check out the entire list of companies who have already received approval for Xaracoll's generic
Alternative Brands for Xaracoll
Xaracoll which is used for providing post-surgical analgesia through local anesthesia for up to 24 hours following implantation., has several other brand drugs using the same active ingredient (Bupivacaine Hydrochloride). Given below is the list of those companies and their brand drugs, to help you identify new opportunities, assess competitors, and plan your market strategies more effectively.
| Drug Owner | Drug Name | |
|---|---|---|
| Purdue Pharma Lp |
|
Apart from brand drugs containing the same ingredient, some generics have also been filed for Bupivacaine Hydrochloride, Xaracoll's active ingredient. Check the complete list of approved generic manufacturers for Xaracoll
About Xaracoll
Xaracoll is a drug owned by Innocoll Pharmaceuticals. It is used for providing post-surgical analgesia through local anesthesia for up to 24 hours following implantation. Xaracoll uses Bupivacaine Hydrochloride as an active ingredient. Xaracoll was launched by Innocoll Pharms in 2020.
Approval Date:
Xaracoll was approved by FDA for market use on 28 August, 2020.
Active Ingredient:
Xaracoll uses Bupivacaine Hydrochloride as the active ingredient. Check out other Drugs and Companies using Bupivacaine Hydrochloride ingredient
Treatment:
Xaracoll is used for providing post-surgical analgesia through local anesthesia for up to 24 hours following implantation.
Dosage:
Xaracoll is available in implant form for implantation use. Given below is detailed information on Dosage -
| Strength | Dosage Form | Availability | Application Pathway |
|---|---|---|---|
| 100MG | IMPLANT | Discontinued | IMPLANTATION |